Tekla Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Tekla Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-119,324	Closed	-$7.93M	–	188
2021 Q3	$7.93M	Hold	119,324	–	–	0.26%	84
2021 Q2	$9.31M	Hold	119,324	–	–	0.3%	86
2021 Q1	$11.3M	Hold	119,324	–	–	0.39%	66
2020 Q4	$14.5M	Buy	119,324 +113,647	+2,002%	+$12.5M	0.51%	57
2020 Q3	$496K	Hold	5,677	–	–	0.02%	195
2020 Q2	$367K	Hold	5,677	–	–	0.01%	212
2020 Q1	$254K	Hold	5,677	–	–	0.01%	206
2019 Q4	$354K	Buy	+5,677	New	+$270K	0.01%	201

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Tekla Capital Management's TPTX Position: Q4 2021 in Review

Tekla Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 119,324 shares — an estimated $7.93M sold.

Tekla Capital Management first reported a position in TPTX in Q4 2019 and held it in 8 quarters. The position peaked at $14.5M in Q4 2020. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Tekla Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Tekla Capital Management sold 119,324 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $7.93M.
Tekla Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
Tekla Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $14.5M in Q4 2020.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.